Lp-PLA₂ as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis

References

• Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999 Aug 02;261:511–514.
   PubMed Web of Science ®Google Scholar
• Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002 Dec;3:57–68.
   PubMed Web of Science ®Google Scholar
• Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009 May;1791:327–338.
   PubMed Web of Science ®Google Scholar
• Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2011 Mar;2:27–38.
   PubMedGoogle Scholar
• Ge PC, Chen ZH, Pan RY, et al. Synergistic effect of lipoprotein-associated phospholipase a2 with classical risk factors on coronary heart disease: a multi-ethnic study in China. Cell Physiol Biochem. 2016;40:953–968.
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000 Jun;150:413–419.
   PubMed Web of Science ®Google Scholar
• Garg PK, McClelland RL, Jenny NS, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: the multi ethnic study of atherosclerosis. Atherosclerosis. 2015;241(1):176–182.
   PubMed Web of Science ®Google Scholar
• Katan M, Moon YP, Paik MC, et al. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the northern Manhattan study. PLoS One. 2014;9:e83393.
   PubMed Web of Science ®Google Scholar
• Han L, Zhong C, Bu X, et al. Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke. Atherosclerosis. 2017;266:1–7.
   PubMed Web of Science ®Google Scholar
• Wei L, Ke Z, Zhao Y, et al. The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction. Neuroreport. 2017;28(6):325–330.
   PubMed Web of Science ®Google Scholar
• Elkind MS, Tai W, Coates K, et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006 Oct 23;166:2073–2080.
   PubMed Web of Science ®Google Scholar
• Elkind MS, Tai W, Coates K, et al. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis. 2009;27:42–50.
   PubMed Web of Science ®Google Scholar
• Cucchiara BL, Messe SR, Sansing L, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke. 2009;40:2332–2336.
   PubMed Web of Science ®Google Scholar
• Delgado P, Chacon P, Penalba A, et al. Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovasc Dis. 2012;33:150–158.
   PubMed Web of Science ®Google Scholar
• Adams HP Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35–41.
   PubMed Web of Science ®Google Scholar
• Arboix A, Cabeza N, García-Eroles L, et al. Relevance of transient ischemic attack to early neurological recovery after nonlacunar ischemic stroke. Cerebrovasc Dis. 2004;18(4):304–311.
   PubMed Web of Science ®Google Scholar
• Zhuo S, Wolfert RL, Yuan C. Biochemical differences in the mass and activity tests of lipoprotein-associated phospholipase A2 explain the discordance in results between the two assay methods. Clin Biochem. 2017;50(18):1209–1215.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Smith DA, Mehta AE, et al. American association of clinical endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012 Mar-Apr;18:1–78. Suppl 1.
   PubMedGoogle Scholar
• Kwon HM, Lee YS, Bae HJ, et al. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke. 2014;45(3):871–873.
   PubMed Web of Science ®Google Scholar
• Tsai TH, Chen YL, Lin HS, et al. Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke. J Atheroscler Thromb. 2012;19:523–531.
   PubMed Web of Science ®Google Scholar
• Kara H, Akinci M, Degirmenci S, et al. High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke. Neuropsychiatr Dis Treat. 2014;10:1451–1457.
   PubMed Web of Science ®Google Scholar
• Lin J, Zheng H, Cucchiara BL, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke. Neurology. 2015 Nov 03;85:1585–1591.
   PubMed Web of Science ®Google Scholar
• Maiolino G, Bisogni V, Rossitto G, et al. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol. 2015 Oct 26;7:609–620.
   PubMed Web of Science ®Google Scholar
• Bonnefont-Rousselot D. [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques]. Ann Pharm Fr. 2016 May;74:190–197.
   PubMedGoogle Scholar
• Marsche G. Lp-PLA2, plaque inflammation and lesion development vary fundamentally between different vascular sites. J Am Heart Assoc. 4:2015 Feb 11.
   Web of Science ®Google Scholar
• Benderly M, Sapir B, Kalter-Leibovici O, et al. Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers. 2017 May - Jun;22(3-4):219-224.
   Web of Science ®Google Scholar
• Elkind MS, Leon V, Moon YP, et al. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke. 2009 Oct;40:3233–3237.
   PubMed Web of Science ®Google Scholar
• Arboix A, Miguel M, Císcar E, et al. Cardiovascular risk factors in patients aged 85 or older with ischemic stroke. Clin Neurol Neurosurg. 2006;108(7):638.
   PubMed Web of Science ®Google Scholar